The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.
Confirmed diagnosis of non-squamous NSCLC, Stage IIIB/IIIC incurable or IV/M1.
Age ≥ 18 years at diagnosis of advanced/metastatic disease.
failure of platinum-based chemotherapy,
failure of ≥ 1 line of approved target therapy or no targeted therapy available at the clinic,
Patients with evidence of other primary malignancies (except basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both study cohorts.
Patients who participated in a clinical investigational study for the treatment of any cancer, including NSCLC, or any early access program from 2018 onwards.
The study population will consist of sequential adult patients in study sites with a diagnosis of IIIB/IIIC/IV non-squamous NSCLC with or without AGA and received at least 1 line of treatment after failing PTC for a/m NSCLC with a treatment start date between January 2017 and December 2024.
Cohort
Retrospective
Not listed
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: tumor histology, mutation and PD-L1 status, disease stage at diagnosis
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: disease stage at diagnosis
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: smoking status
Describe the patient population and treatment patterns
Description of patient population and treatment patterns: age
Click on the lead sponsor to view all of their trials.
